Allergan PLC. (NYSE:AGN) – Equities research analysts at William Blair reduced their FY2019 earnings per share estimates for Allergan PLC. in a report issued on Monday. William Blair analyst T. Lugo now forecasts that the company will earn $17.68 per share for the year, down from their prior estimate of $18.90.
AGN has been the topic of a number of other reports. Royal Bank Of Canada reduced their target price on shares of Allergan PLC. from $277.00 to $250.00 and set an “outperform” rating on the stock in a report on Thursday. They noted that the move was a valuation call. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a report on Monday, June 26th. BidaskClub lowered shares of Allergan PLC. from a “sell” rating to a “strong sell” rating in a report on Friday, August 25th. Mizuho restated a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a report on Monday, September 25th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $258.00 target price on shares of Allergan PLC. in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $263.34.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/fy2019-eps-estimates-for-allergan-plc-agn-lowered-by-analyst.html.
Allergan PLC. (NYSE:AGN) traded up 1.07% during trading on Thursday, hitting $189.16. 7,228,557 shares of the stock traded hands. Allergan PLC. has a 52-week low of $182.80 and a 52-week high of $256.80. The stock has a market cap of $63.24 billion, a P/E ratio of 5.76 and a beta of 1.15. The company’s 50 day moving average price is $213.47 and its 200-day moving average price is $231.01.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the firm posted $3.35 earnings per share.
A number of institutional investors and hedge funds have recently bought and sold shares of AGN. Waldron LP acquired a new stake in Allergan PLC. during the 1st quarter worth approximately $348,000. Mirae Asset Global Investments Co. Ltd. increased its position in Allergan PLC. by 246.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 113,582 shares of the company’s stock worth $27,137,000 after purchasing an additional 80,829 shares in the last quarter. Neville Rodie & Shaw Inc. increased its position in Allergan PLC. by 11.0% during the 1st quarter. Neville Rodie & Shaw Inc. now owns 3,074 shares of the company’s stock worth $734,000 after purchasing an additional 305 shares in the last quarter. Airain ltd acquired a new stake in Allergan PLC. during the 1st quarter worth approximately $241,000. Finally, Ingalls & Snyder LLC increased its position in Allergan PLC. by 20.6% during the 1st quarter. Ingalls & Snyder LLC now owns 1,254 shares of the company’s stock worth $300,000 after purchasing an additional 214 shares in the last quarter. 81.94% of the stock is owned by hedge funds and other institutional investors.
Allergan PLC. announced that its Board of Directors has initiated a stock buyback plan on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.